Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-085833 · Präparat HOS-083204
Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40 % increase in
lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did
not interact. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is
necessary (see section 4.2). Lamivudine has no effect on the pharmacokinetics of trimethoprim or
sulfamethoxazole. When concomitant administration is warranted, patients should be monitored
clinically. Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage bab8759d1b8b928fe978dcbb012c30553386f66b6074e11ac1a0d8b8a003dd4c · Zeichen 196–849 im Abschnitt
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-085834 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 21
HOS-085871 · Präparat HOS-083204
Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40 % increase in
lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did
not interact. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is
necessary (see section 4.2). Lamivudine has no effect on the pharmacokinetics of trimethoprim or
sulfamethoxazole. When concomitant administration is warranted, patients should be monitored
clinically. Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage bab8759d1b8b928fe978dcbb012c30553386f66b6074e11ac1a0d8b8a003dd4c · Zeichen 196–849 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 21
HOS-085872 · Präparat HOS-083204
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 851–1387 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088512 · Präparat HOS-083663
Drugs by Therapeutic Area
Interaction Recommendation
Geometric mean change (%) concerning co-
(Possible mechanism) administration
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Didanosine /Zidovudine Interaction not studied.
Stavudine/Lamivudine Interaction not studied. Combination not
Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended.
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Lamivudine Interaction not studied. As only limited data available
Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is
(750 mg twice daily with Atovaquone AUC unknown.
food/200 mg thrice daily)
Clarithromycin/Lamivudine Interaction not studied. Separate administration of
Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin
(500 mg twice daily/100 mg by at least 2 hours
every 4 hours)
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage
(Co-trimoxazole)/Lamivudine adjustment necessary, unless
(160 mg/800 mg once daily for Trimethoprim: AUC patient has renal impairment
5 days/300 mg single dose) Sulfamethoxazole: AUC (See Section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage ef0dd78ec8fb1f808137e8f5128b1cd7fa4540efa9cc39a15103836ffbdd97d9 · Zeichen 1146–3116 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088513 · Präparat HOS-083663
(organic cation transporter When concomitant
inhibition) administration with co-
Trimethoprim/sulfamethoxazole Interaction not studied. trimoxazole is warranted,
(Co-trimoxazole)/Zidovudine patients should be monitored
clinically. High doses of
trimethoprim/
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage a5b5ecc033f9627aa4197b73f6ecfc4795888cbbf3b59b8698319c08ba2953d6 · Zeichen 3149–3685 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-089935 · Präparat HOS-083949
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-089937 · Präparat HOS-083949
Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by
about 40 %. Lamivudine had no effect on the pharmacokinetics of trimethoprim or
sulphamethoxazole. However, unless the patient has renal impairment, no dosage adjustment of
lamivudine is necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 98b5c1d4b5032241598ba4f436208e04df9c17132f9b5d18f45b195391f7b63b · Zeichen 892–1185 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 21
HOS-089961 · Präparat HOS-083949
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 22
HOS-089963 · Präparat HOS-083949
Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by
about 40 %. Lamivudine had no effect on the pharmacokinetics of trimethoprim or
sulphamethoxazole. However, unless the patient has renal impairment, no dosage adjustment of
lamivudine is necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage 98b5c1d4b5032241598ba4f436208e04df9c17132f9b5d18f45b195391f7b63b · Zeichen 948–1241 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-108561 · Präparat HOS-093047
8
Stavudine/Zidovudine In vitro antagonism of anti-HIV
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Abacavir Interaction not studied. As only limited data available
Atovaquone/Lamivudine Interaction not studied. the clinical significance is
Atovaquone/Zidovudine Zidovudine AUC 33% unknown.
(750 mg twice daily with Atovaquone AUC
food/200 mg thrice daily)
Clarithromycin/Abacavir Interaction not studied. Separate administration of
Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by
Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours
(500 mg twice daily/100 mg
every 4 hours)
Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment
(Co-trimoxazole)/Abacavir necessary, unless patient has
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section
(Co-trimoxazole)/Lamivudine 4.2).
(160mg/800mg once daily for 5 Trimethoprim: AUC
days/300mg single dose) Sulfamethoxazole: AUC When concomitant
administration with co-
(organic cation transporter trimoxazole is warranted,
inhibition) patients should be monitored
Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of
(Co-trimoxazole)/Zidovudine trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 71bfdfc92b9301a18965d48965dbae21382ab47ace7b98ce7ba0a04318a98c78 · Zeichen 2506–4852 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113477 · Präparat HOS-093937
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine /Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Zidovudine/Abacavir Interaction not studied
Zidovudine/Lamivudine Lamivudine: AUC
Zidovudine 300 mg single dose Zidovudine : AUC
Lamivudine 150 mg single dose
Emtricitabine/Lamivudine Due to similarities, Kivexa
should not be administered
concomitantly with other
cytidine analogues, such as
emtricitabine.
ANTI-INFECTIVE PRODUCTS
Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment
(Co-trimoxazole)/Abacavir necessary.
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40%
(Co-trimoxazole)/Lamivudine When concomitant
(160 mg/800 mg once daily for Trimethoprim: AUC administration with
5 days/300 mg single dose) Sulfamethoxazole: AUC co-trimoxazole is warranted,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113478 · Präparat HOS-093937
7
patients should be monitored
(organic cation transporter clinically. High doses of
inhibition) trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided
ANTIMYCOBACTERIALS
Rifampicin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Rifampicin/Lamivudine Interaction not studied.
ANTICONVULSANTS
Phenobarbital/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Phenobarbital/Lamivudine Interaction not studied.
Phenytoin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations Monitor phenytoin
through UGT induction. concentrations.
Phenytoin/Lamivudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) phenobarbital (HOS-085617) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 387827645b1a19ba72bcdce583c6ff15cfaff9ba9910317f65a1827bc65c4f3b · Zeichen 3272–5207 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118455 · Präparat HOS-094825
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is
administered without CYP3A4 inhibitors. In vitro studies have shown that maraviroc does not
inhibit any of the major renal uptake transporters at clinically relevant concentrations (OAT1,
OAT3, OCT2, OCTN1, and OCTN2). Additionally, co-administration of maraviroc with tenofovir
(substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport
inhibitor), showed no effect on the pharmacokinetics of maraviroc. In addition, co-administration
of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily
renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics.
Maraviroc inhibits P-glycoprotein in vitro (IC50 is 183 μM). However, maraviroc does not
significantly affect the pharmacokinetics of digoxin in vivo. It may not be excluded that maraviroc
can increase the exposure to the P-glycoprotein substrate dabigatran etexilate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) trimethoprim (HOS-085184) digoxin (HOS-086172) lamivudine (HOS-085829) zidovudine (HOS-085837) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 6e9f4ecd97f539896aacf725a92a940b796bdc8720e11860c99c90991dcb4097 · Zeichen 1398–2427 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 34
HOS-118500 · Präparat HOS-094825
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is
administered without CYP3A4 inhibitors. In vitro studies have shown that maraviroc does not
inhibit any of the major renal uptake transporters at clinically relevant concentrations (OAT1,
OAT3, OCT2, OCTN1, and OCTN2). Additionally, co-administration of maraviroc with tenofovir
(substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport
inhibitor), showed no effect on the pharmacokinetics of maraviroc. In addition, co-administration
of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily
renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics.
Maraviroc inhibits P-glycoprotein in vitro (IC50 is 183 μM). However, maraviroc does not
significantly affect the pharmacokinetics of digoxin in vivo. It may not be excluded that maraviroc
can increase the exposure to the P-glycoprotein substrate dabigatran etexilate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) trimethoprim (HOS-085184) digoxin (HOS-086172) lamivudine (HOS-085829) zidovudine (HOS-085837) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 6e9f4ecd97f539896aacf725a92a940b796bdc8720e11860c99c90991dcb4097 · Zeichen 1454–2483 im Abschnitt
Wechselwirkungen · Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211901 · Präparat HOS-154784
Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40% increase in
lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did
not interact. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is
necessary (see section 4.2). Lamivudine has no effect on the pharmacokinetics of trimethoprim or
sulfamethoxazole. When concomitant administration is warranted, patients should be monitored
clinically. Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage e8a7506dd7614242257eac5ae343ff4aff7beba39b9f41538cbccef23f1853b3 · Zeichen 139–791 im Abschnitt
Wechselwirkungen · Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211903 · Präparat HOS-154784
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 793–1329 im Abschnitt
Wechselwirkungen · Lamivudine Teva
Lamivudine Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211991 · Präparat HOS-154800
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-07T02:00:00Z · SHA-256 7ebfd130ef9d9ca18166e2a55526570d39c018726558f43f8bad673f541d0883 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Lamivudine Teva
Lamivudine Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211992 · Präparat HOS-154800
Substances shown to be predominately excreted either via the active organic anionic pathway, or by
glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.
Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by
about 40 %. Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole.
However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-07T02:00:00Z · SHA-256 7ebfd130ef9d9ca18166e2a55526570d39c018726558f43f8bad673f541d0883 · Passage af16350f5f33a63c038e2a04b8faa0f06982b1c58aacea5c74862ad9fb357722 · Zeichen 695–1184 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129231 · Präparat HOS-096703
Lamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through
the OCT2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an
inhibitor of these drug transporters) has been shown to increase lamivudine plasma concentrations,
however the resulting increase was not clinically significant (see Table 1). Dolutegravir is an OCT2
and MATE1 inhibitor; however, lamivudine concentrations were similar with or without co-
administration of dolutegravir based on a cross study analysis, indicating that dolutegravir has no
effect on lamivudine exposure in vivo. Lamivudine is also substrate of the hepatic uptake transporter
OCT1. As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due
to inhibition of OCT1 are unlikely to be of clinical significance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 1e1656ecc145f4ec53e820ca5237ea28fa5aa2085a4f6d0e0b88cd9a4e2bee02 · Zeichen 1376–2230 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.